Improvements in Clinical Outcomes Associated with Reduction in Hyperinflation with Zephyr Valves
F. Sciurba (Pittsburgh, United States of America), R. Sue (Phoenix, United States of America), H. Rivas-Perez (Louisville, United States of America), B. Morrissey (Sacramento, United States of America), H. Goulart De Oliveira (Porto Alegre, Brazil), M. Wahidi (Durham, United States of America), P. F G Cardoso (Sao Paulo, Brazil), N. Pastis Jr (Charleston, United States of America), M. Dransfield (Birmingham, United States of America), P. Shah (London, United Kingdom), S. Radhakrishnan (Redwwod City, United States of America), N. Shargill (Redwwod City, United States of America), G. Criner (Philadelphia, United States of America), D. Slebos (Groningen, Netherlands)
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Sciurba (Pittsburgh, United States of America), R. Sue (Phoenix, United States of America), H. Rivas-Perez (Louisville, United States of America), B. Morrissey (Sacramento, United States of America), H. Goulart De Oliveira (Porto Alegre, Brazil), M. Wahidi (Durham, United States of America), P. F G Cardoso (Sao Paulo, Brazil), N. Pastis Jr (Charleston, United States of America), M. Dransfield (Birmingham, United States of America), P. Shah (London, United Kingdom), S. Radhakrishnan (Redwwod City, United States of America), N. Shargill (Redwwod City, United States of America), G. Criner (Philadelphia, United States of America), D. Slebos (Groningen, Netherlands). Improvements in Clinical Outcomes Associated with Reduction in Hyperinflation with Zephyr Valves. 3374
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: